Jeil Pharmaceutical Co.,Ltd

A271980

KR7271980005

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
16,640 ^KRW	+0.42%		-0.12%	-2.69%

2023	Jeil Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
2022	Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.	CI

Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.

December 13, 2022 at 12:39 am EST

From October 1, 2022 to December 9, 2022, the company has repurchased 0 shares, representing 0% for KRW 0 million. With this, the company has completed the repurchase of 42,941 shares, representing 0.29% for KRW 1,521.88 million under the buyback announced on December 10, 2020.

Latest news about Jeil Pharmaceutical Co.,Ltd

Jeil Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.	22-12-13	CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.	22-12-13	CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.	22-12-13	CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.	22-12-13	CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.	22-12-13	CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback announced on December 10, 2020, has expired with 42,941 shares, representing 0.29% for KRW 1,521.88 million.	22-12-08	CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan Extended till December 9, 2022.	22-06-08	CI
Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in South Korea	22-01-13	CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan Extended till June 9, 2022.	21-12-08	CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback announced on December 10, 2020, has expired.	21-12-08	CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan Extended till December 09, 2021.	21-06-08	CI
Rockwell Medical, Inc. Announces Submission of Triferic® New Drug Application in South Korea by Partner, Jeil Pharmaceutical Co., Ltd	21-02-01	CI
Jeil Pharmaceutical Co.,Ltd announces an Equity Buyback for KRW 3,000 million worth of its shares.	20-12-10	CI
Jeil Pharmaceutical Co.,Ltd authorizes a Buyback Plan.	20-12-09	CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on May 16, 2019.	20-05-14	CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback announced on May 16, 2019, has expired with 84,920 shares, representing 0.58% for KRW 2,707.67 million.	20-05-14	CI
Jeil Pharmaceutical Co.,Ltd announces an Equity Buyback for KRW 3,000 million worth of its shares.	19-05-15	CI
Jeil Pharmaceutical Co.,Ltd authorizes a Buyback Plan.	19-05-15	CI
Jeil Pharma Holdings Inc completed the acquisition of additional 35.2% stake in Jeil Pharmaceutical Co.,Ltd for approximately KRW 250 billion.	18-11-15	CI
Jeil Pharma Holdings Inc made an offer to acquire an additional 47.6% stake in Jeil Pharmaceutical Co.,Ltd for approximately KRW 490 billion.	18-10-01	CI
Jeil Pharma Holdings Inc acquired 13.53% stake in Jeil Pharmaceutical Co.,Ltd.	18-05-01	CI
Jeil Pharmaceutical Co.,Ltd(KOSE:) added to S&P Global BMI Index	17-07-17	CI
Jeil Pharmaceutical Co., Ltd. announced the spin-off of its pharmaceuticals manufacturing and sales business.	17-01-15	CI

Chart Jeil Pharmaceutical Co.,Ltd

Duration

Period

More charts

Company Profile

JEIL PHARMACEUTICAL CO.,LTD is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company provides anti-inflammatory painkillers, anticancer drugs, gastritis drugs, antibiotics, ulcer treatments, antidepressant drugs, pollakisuria and incontinence treatments, impetigo drugs, septicemia treatments, hyperlipidemia treatments, peripheral neuropathic pain drugs, hypertension drugs and others. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
JEIL PHARMACEUTICAL CO.,LTD	-2.69%	175M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.27%	43.18B
OTSUKA HOLDINGS CO., LTD.	+24.05%	23.23B
SANDOZ GROUP AG	+15.11%	14.6B
ZYDUS LIFESCIENCES LIMITED	+38.36%	11.5B
ONO PHARMACEUTICAL CO., LTD.	-7.63%	6.79B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+10.21%	5.31B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-2.27%	4.81B